
Rare FNIP1 Mutations Link Fat Burning to Lower Cardiometabolic Risk
A Nature study of over a million people found rare, protein-truncating FNIP1 mutations that lift a cellular energy brake, nudging the body to burn fat, improve fat distribution, and cut cardiometabolic disease risk by about 60%; lab and mouse experiments support the mechanism, suggesting FNIP1 as a potential drug target, though safety and efficacy of inhibiting FNIP1 are not yet proven.





